Medical Specialty >> OncologyRead article
- Breast Symptoms at Mammogram May Raise Future Cancer Risk
- Could a Pap Test Spot More Than Just Cervical Cancer?
- Task Force Issues Stronger Skin Cancer Prevention Guidelines
- More U.S. Teens Seeing Ads for E-Cigarettes
- H. Pylori Treatment Tied to Lower Metachronous Gastric Cancer Risk
- Blueprint Being Developed to Address Physician Burnout
- Personal Health Info Found in Recycling at Five Hospitals
Robert L. Coleman, MD. Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of… Elizabeth M. Swisher, MD. Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity… Bert Vogelstein, MD. Investigators at Johns Hopkins University in Baltimore used complex mathematical modeling to track mutations driving abnormal cell growth for 32 types of cancer. From their calculations, the researchers believe that the bulk of cancers are caused by random DNA copying errors (replicative mutations).…
Great articles. learnt a lot from it.